Status:
TERMINATED
CD8+ T-cell PET/CT Imaging in COVID-19 Patients
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
ImaginAb, Inc.
Conditions:
Lymphopenia Due to COVID-19
T-cell
Eligibility:
All Genders
50+ years
Brief Summary
A subset of patients diagnosed with severe acute respiratory syndrome (SARS)-CoV2 infection present with lymphopenia. The degree of lymphopenia, and in particular reduced cluster of differentiation (C...
Detailed Description
Rationale: A subset of patients diagnosed with SARS-CoV2 infection present with lymphopenia. The degree of lymphopenia, and in particular reduced CD8+ T-cell numbers, is strongly correlated with clini...
Eligibility Criteria
Inclusion
- a microbiologically proven SARS-CoV2 infection
- More than 50 years of age;
- Ability to provide written informed consent.
Exclusion
- Contra-indication for PET: Pregnancy, Breast-feeding, Severe claustrophobia.
- Contra-indication for administration of iodine-containing contrast agents
- Other serious illness, e.g. history of malignancies or auto-immune disorders
- Known pre-existing lymphopenia from an unrelated other medical condition
- Estimated creatinine clearance ≤ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method) OR oligo-uric patients (\<400 mL/24hr)
Key Trial Info
Start Date :
February 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04874818
Start Date
February 14 2022
End Date
December 31 2022
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud university medical center
Nijmegen, Gelderland, Netherlands, 6500HB